Skip to main content
Erschienen in: Drug Safety 6/2014

01.06.2014 | Original Research Article

Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries

verfasst von: Florence Margraff, Delphine Bertram

Erschienen in: Drug Safety | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The modalities and contributions to drug safety of patient adverse drug reaction reporting systems in 50 countries have been reviewed and analysed.

Methods

The means made available by National Health Competent Authorities (NCAs) for patients to report drug side effects were compared through literature review and questionnaire.

Results

Among the 50 countries included in this study, we found that direct patient reporting systems exist in 44 countries and represent 9 % of total reports, the rest coming from healthcare professionals. Australia was the first, in 1964, and the United States has the system in which patients are the most involved. A total of 27 countries have a patient-specific reporting form, and 31 countries provide a form to complete online. In order to help patients, four countries constrain the description of the reaction and 12 constrain the choice of drug on the reporting form. Most of the surveyed countries request the patient’s medical history (30 countries) and concomitant therapies (41 countries). The total number of fields per form ranges from 6 to 59, with a mean of 36 items.

Conclusions

Most of the surveyed countries have implemented a patient adverse drug reaction reporting system. From this study, it seems that an online reporting form increases the rate of reporting. Currently, many different forms exist worldwide; these should be harmonized by considering the strengths and weaknesses of all existing forms. But above all, to increase the number of reports, each country should promote NCA-initiated adverse drug reactions reporting systems.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products; 2010. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf. Accessed 21 Oct 2013. REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products; 2010. http://​ec.​europa.​eu/​health/​files/​eudralex/​vol-1/​reg_​2010_​1235/​reg_​2010_​1235_​en.​pdf. Accessed 21 Oct 2013.
3.
Zurück zum Zitat Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use—article 107a. Official Journal L. 2004;311:67–128. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use—article 107a. Official Journal L. 2004;311:67–128.
5.
Zurück zum Zitat Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ. 1996;313(7056):530–1.PubMedCentralPubMedCrossRef Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ. 1996;313(7056):530–1.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat De Langen J, Van Hunsel F, Passier A, De Jong-Van den Berg L, Van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31(6):515–24.PubMedCrossRef De Langen J, Van Hunsel F, Passier A, De Jong-Van den Berg L, Van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31(6):515–24.PubMedCrossRef
7.
Zurück zum Zitat Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56.PubMedCentralPubMedCrossRef Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Cumber SL, Heffer SJ, Gandhi S, Avery AJ. The Yellow Card Scheme: experience of patient reporting of adverse drug reactions 5 years since launch. Pharmacoepidemiol Drug Saf. 2010;19:S321. Cumber SL, Heffer SJ, Gandhi S, Avery AJ. The Yellow Card Scheme: experience of patient reporting of adverse drug reactions 5 years since launch. Pharmacoepidemiol Drug Saf. 2010;19:S321.
10.
Zurück zum Zitat Van Hunsel F, Härmark L, Pal S, Olsson S, Van Grotheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60.PubMedCrossRef Van Hunsel F, Härmark L, Pal S, Olsson S, Van Grotheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60.PubMedCrossRef
12.
Zurück zum Zitat Van Hunsel F, Talsma A, Van Puijenbroek E, De Jong-Van den Berg L, Van Grootheest K. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case–control study. Pharmacoepidemiol Drug Saf. 2011;20(3):286–91.PubMedCrossRef Van Hunsel F, Talsma A, Van Puijenbroek E, De Jong-Van den Berg L, Van Grootheest K. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case–control study. Pharmacoepidemiol Drug Saf. 2011;20(3):286–91.PubMedCrossRef
13.
Zurück zum Zitat Hazell L, Cornelius V, Shakir S, Avery AJ. Patient reporting of adverse drug reactions in the UK: potential signals generated by patients compared to healthcare professionals [poster abstract no. 227]. Pharmacoepidemiol Drug Saf. 2010;19(Suppl. 1):S97–8. Hazell L, Cornelius V, Shakir S, Avery AJ. Patient reporting of adverse drug reactions in the UK: potential signals generated by patients compared to healthcare professionals [poster abstract no. 227]. Pharmacoepidemiol Drug Saf. 2010;19(Suppl. 1):S97–8.
14.
Zurück zum Zitat Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ. How do patients contribute to signal detection? Drug Saf. 2013;36(3):199–206.PubMedCrossRef Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ. How do patients contribute to signal detection? Drug Saf. 2013;36(3):199–206.PubMedCrossRef
15.
Zurück zum Zitat White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc. 2013;20(3):404–8.PubMedCentralPubMedCrossRef White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc. 2013;20(3):404–8.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Banerjee AK, Okun S, Edwards IR, Wicks P, Smith M, Mayall S, Flamion B, Cleland C, Basch E. Patient-reported outcome measures in safety event reporting—PROSPER consortium guidance. Drug Saf. 2013;36:1129–49.PubMedCentralPubMedCrossRef Banerjee AK, Okun S, Edwards IR, Wicks P, Smith M, Mayall S, Flamion B, Cleland C, Basch E. Patient-reported outcome measures in safety event reporting—PROSPER consortium guidance. Drug Saf. 2013;36:1129–49.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Van Hunsel F, Van der Welle C, Passier A, Van Puijenbroek E, Van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–50.PubMedCentralPubMedCrossRef Van Hunsel F, Van der Welle C, Passier A, Van Puijenbroek E, Van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–50.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Van Hunsel F, Ten Berge EA, Borgsteede SD, Van Grootheest K. What motivates patients to report an adverse drug reaction? Ann Pharmacother. 2010;44(5):936–7.PubMedCrossRef Van Hunsel F, Ten Berge EA, Borgsteede SD, Van Grootheest K. What motivates patients to report an adverse drug reaction? Ann Pharmacother. 2010;44(5):936–7.PubMedCrossRef
19.
Zurück zum Zitat Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806–22.PubMedCentralPubMedCrossRef Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806–22.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Hoffmann E, Fouretier A, Vergne C, Bertram D. Pharmacovigilance regulatory requirements in Latin America. Pharm Med. 2012;26:1–12.CrossRef Hoffmann E, Fouretier A, Vergne C, Bertram D. Pharmacovigilance regulatory requirements in Latin America. Pharm Med. 2012;26:1–12.CrossRef
22.
Zurück zum Zitat Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.CrossRef Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.CrossRef
24.
Zurück zum Zitat The Erice declaration: the critical role of communication in drug safety. Hugman B Drug Saf. 2006;29(1):91–3. The Erice declaration: the critical role of communication in drug safety. Hugman B Drug Saf. 2006;29(1):91–3.
25.
Zurück zum Zitat Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234, iii–iv. Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234, iii–iv.
26.
Zurück zum Zitat Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684–6.PubMedCrossRef Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684–6.PubMedCrossRef
29.
Zurück zum Zitat Singh A, Bhatt P. Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. J Pharmacol Pharmacother. 2012;3(3):228–32.PubMedCentralPubMedCrossRef Singh A, Bhatt P. Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. J Pharmacol Pharmacother. 2012;3(3):228–32.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689–703.PubMedCrossRef Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689–703.PubMedCrossRef
31.
Zurück zum Zitat Chiahemen T. Interview: how NAFDAC checkmates adverse drug reaction with PRASCOR—Mrs. Osakwe. National Accord Newspaper; 2013. Chiahemen T. Interview: how NAFDAC checkmates adverse drug reaction with PRASCOR—Mrs. Osakwe. National Accord Newspaper; 2013.
Metadaten
Titel
Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries
verfasst von
Florence Margraff
Delphine Bertram
Publikationsdatum
01.06.2014
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 6/2014
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0162-y

Weitere Artikel der Ausgabe 6/2014

Drug Safety 6/2014 Zur Ausgabe